United States: Sequenom Asks The Supreme Court To Clarify The Limits On Section 101

On March 21, 2016, Sequenom filed a writ of certiorari with the U.S. Supreme Court, asking the Court to provide clarification regarding the limits of 35 U.S.C §101 as it relates to patent eligibility of diagnostic tests. Sequenom's petition presents the following question:

Whether a novel method is patent-eligible where:

(1) a researcher is the first to discover a natural phenomenon;

(2) that unique knowledge motivates him to apply a new combination of known techniques to that discovery; and

(3) he thereby achieves a previously impossible result without preempting other uses of the discovery?

Petition for Writ of Certiorari at i, Sequenom, Inc., v. Ariosa Diagnostic, Inc., No. 15-1182 (March 21, 2016). The petition offers the Court the opportunity to loosen the seemingly universal prohibition against diagnostic method claims set forth in Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289 (2012).

Sequenom is the exclusive licensee of U.S. Patent No. 6,258,540 (the '540 patent), which claims a "method of detecting paternally inherited nucleic acid of fetal origin performed on the maternal serum or plasma sample from a pregnant female." '540 patent at 23:61-63. According to Sequenom, the inventors of the patented subject matter "discovered that 'cell-free' fetal DNA (cffDNA) was circulating in pregnant women's plasma in surprising concentrations." Petition at p. 2. The inventors further discovered that, by identifying paternal DNA in the maternal plasma, the fetal DNA could be identified, enabling the diagnosis of certain fetal genetic conditions. Id. This discovery is said to have "revolutionized [the] field" (id.) as previous researchers searching for noninvasive tests to detect fetal genetic material sought to "meticulously comb[ ] the cellular portion of maternal blood for fetal cells, and routinely discarded the rest of their maternal blood samples – the plasma and serum – as waste." Id. at 1. According the Sequenom, the inventors:

[D]evised an early-prenatal genetic test whose key steps – never previously combined in this way – were to take a maternal blood sample, keep only the long discarded non-cellular fraction, amplify the cell-free DNA only they had discovered therein, and search for paternally inherited sequences whose presence or quantity indicated diagnostically relevant conditions.

Id. at p. 3. Independent claims 1 and 21 of the '540 patent recite:

  1. A method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female, which method comprises
    amplifying a paternally inherited nucleic acid from the serum or plasma sample and
    detecting the presence of a paternally inherited nucleic acid of fetal origin in the sample.
  1. A method of performing a prenatal diagnosis, which method comprises the steps of:

(i) providing a maternal blood sample;
(ii) separating the sample into a cellular and a non-cellular fraction;
(iii) detecting the presence of a nucleic acid of foetal origin in the non-cellular fraction according to the method of claim 1;
(iv) providing a diagnosis based on the presence and/or quantity and/or sequence of the foetal nucleic acid.

Sequenom requests that the Court grant the petition because "[t]his is as straightforward a certiorari candidate as any patent case can be." Petition at p. 10. Sequenom points to the fact that, in affirming the district court's ruling that the patent is directed to patent-ineligible subject matter and denying en banc review, several Federal Circuit judges indicated that their hands were tied by the Court's previous decision in Mayo. For example, in affirming the district court's decision, Judge Linn wrote that he was "bound by the sweeping language of the test set out in Mayo." Ariosa Diagnostic, Inc. v. Sequenom, Inc., 788 F.3d 1380 (Fed. Cir. 2015).1 Sequenom argues that "[h]ere, unlike Mayo, every intuition points towards patent-eligibility. And yet the Federal Circuit felt compelled by Mayo to condemn this meritorious patent – and, a fortiori, the patents underlying an entire, vital field of American healthcare innovation." Petition at p. 11.

According to Sequenom, this is a perfect case to provide clarification on the limits of Section 101, because:

[T]he Court can brighten the line between a method that merely adds a new discovery to what practitioners were already doing, see Mayo, 132 S. Ct. at 1299, and one that, by the Federal Circuit's own description, "combine[s] ... man-made tools ... in a new way" to achieve a revolutionary result. . . . Put otherwise, this case allows the Court to emphasize that a new combination of otherwise conventional techniques is patent-eligible even if it is straightforwardly motivated by a patentee's unique discovery of a natural law or phenomenon.

Id. at p. 12; emphasis in original. Sequenom argues that the current state of the law weakens the patent system and poses a danger to life science innovators. See, id. at p. 12 ("Right now, Section 101 doctrine lacks any discernible [sic] limits, and so no company can trust in the patent system when deciding whether to invest in bringing an invention to market. This issue has become particularly life-threatening to life-science innovators."); id. at p. 31 ("[T]he decision below threatens to destroy the predictability and certainty the patent system needs to do its job.")

The Federal Circuit's displeasure with the Court's ruling in Mayo is clear from the various opinions in this case. Mayo, together with the Court's decision in Association for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013), has significantly reduced the ability to obtain patentable subject matter in the life science arena. As the courts and USPTO continue to expand the scope of those rulings beyond correlations between metabolite levels and adjusting drug dosages (Mayo) and isolated DNA (Myriad), biotech and pharmaceutical companies struggle with deciding whether or not to pursue a patent or keep the invention hidden from the public as a trade secret. The dangers of this are clear; less patent protection in this space equates to less investment and ultimately less innovation. Furthermore, as patents disclose to the public how to make and use the invention, having fewer patents decreases the public's knowledge in this space.

While clarification of the scope of Section 101 as it relates to laws of nature and abstract ideas would be extremely valuable to the biotech and pharmaceutical industry as a whole, it is yet to be seen if this case offers the best opportunity to obtain such clarity. Claim 1 recites "amplifying a paternally inherited nucleic acid from the serum or plasma sample and detecting the presence of a paternally inherited nucleic acid of fetal origin in the sample." Sequenom argues that the "combined steps were anything but 'conventional' because 'convention' was the opposite." Petition at p. 5; emphasis added. In other words, while researchers knew how to perform these steps, they were not performing them in the same manner as the claimed methods because the material on which the steps were performed was discarded as waste. Thus, this case offers the Court the opportunity to address whether or not "a new combination of otherwise conventional techniques is patent-eligible even if it is straightforwardly motivated by a patentee's unique discovery of a natural law or phenomenon." Id. at p. 12. Should the court rule that this subject matter is patentable, the scope of patentability under 101 will expand greatly since the ruling in Mayo. A denial of the petition or a ruling that the claims do not recite patentable subject matter, however, will not forever foreclose patenting in this space. Rather, new strategies will need to be developed to obtain patentable subject matter. At the very least, let's hope the Court provides clarity as to what is, rather than what is not, patentable in this area.

Ariosa has until April 20, 2016 (extendable with permission from the Court), to file a brief in opposition. As indicated by the number of amici briefs filed in the Federal Circuit, this case is sure to be closely monitored by biotech and pharmaceutical companies, associations, practitioners, professors, universities, international interests, the USPTO, and more.

Footnote

[1] For further review of the lower court decisions, see http://www.ipintelligencereport.com/2015/12/08/federal-circuit-denies-en-banc-review-of-ariosa-v-sequenom/

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.